Influenza C virus susceptibility to antivirals with different mechanisms of action

  • Antimicrob Agents Chemother. 2024 May 2;68(5):e0172723. doi: 10.1128/aac.01727-23.
Anton Chesnokov  1 ,  Andrei A Ivashchenko  2 ,  Yoko Matsuzaki  3 ,  Emi Takashita  4 ,  Vasiliy P Mishin  1 ,  Alexandre V Ivachtchenko  2  5 ,  Larisa V Gubareva  1
Affiliations
  • 1. Influenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • 2. ChemDiv, San Diego, California, USA.
  • 3. Department of Infectious Diseases, Yamagata University Faculty of Medicine, Yamagata, Japan.
  • 4. Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan.
  • 5. AVISA LLC, Hallandale Beach, Florida, USA.
PMID: 38587392 DOI: 10.1128/aac.01727-23
Abstract

Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent Endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC50 8-22 nM) against type C viruses from six lineages. Banana lectin and a monoclonal antibody, YA3, targeting the hemagglutinin-esterase protein effectively neutralized some, but not all, type C viruses.

Keywords
baloxavir; cap-dependent endonuclease inhibitors; drug susceptibility; lectin; polymerase.
Products